Show simple item record

dc.contributor.authorBryden, A A G
dc.contributor.authorHoyland, Judith A
dc.contributor.authorFreemont, Anthony J
dc.contributor.authorClarke, Noel W
dc.contributor.authorSchembri Wismayer, D
dc.contributor.authorGeorge, Nicholas J
dc.date.accessioned2009-09-08T10:48:57Z
dc.date.available2009-09-08T10:48:57Z
dc.date.issued2002-03
dc.identifier.citationE-cadherin and beta-catenin are down-regulated in prostatic bone metastases. 2002, 89 (4):400-3 BJU Int.en
dc.identifier.issn1464-4096
dc.identifier.pmid11872032
dc.identifier.urihttp://hdl.handle.net/10541/80248
dc.description.abstractOBJECTIVE: To determine the E-cadherin and beta-catenin expression phenotype in untreated primary prostate cancer and corresponding bone metastases. MATERIALS AND METHODS: Paired bone metastasis and primary prostate specimens were obtained from 14 men with untreated metastatic prostate carcinoma. The tumours were histologically graded by an independent pathologist. Expression of mRNA for E-cadherin and beta-catenin was detected within the tumour cells using in-situ hybridization with a 35S-labelled cDNA probe. The expression of E-cadherin and beta-catenin were graded as uniform, heterogeneous or negative. RESULTS: The mRNA for E-cadherin was expressed in 13 of 14 primary carcinomas and 11 bone metastases; beta-catenin was expressed by 13 and nine, respectively. Of the primary tumours, nine expressed E-cadherin and beta-catenin uniformly; in contrast, all metastases had down-regulated E-cadherin and/or beta-catenin. CONCLUSIONS: The down-regulation of E-cadherin and beta-catenin are a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. However, this does not appear to be reflected in the expression of these molecules in the primary tumours.
dc.language.isoenen
dc.subjectBone Canceren
dc.subjectProstatic Canceren
dc.subject.meshBone Neoplasms
dc.subject.meshCadherins
dc.subject.meshCytoskeletal Proteins
dc.subject.meshDown-Regulation
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshProstatic Neoplasms
dc.subject.meshRNA, Messenger
dc.subject.meshTrans-Activators
dc.subject.meshbeta Catenin
dc.titleE-cadherin and beta-catenin are down-regulated in prostatic bone metastases.en
dc.typeArticleen
dc.contributor.departmentChristie and Hope Hospital, University of Manchester, UK.en
dc.identifier.journalBJU Internationalen
html.description.abstractOBJECTIVE: To determine the E-cadherin and beta-catenin expression phenotype in untreated primary prostate cancer and corresponding bone metastases. MATERIALS AND METHODS: Paired bone metastasis and primary prostate specimens were obtained from 14 men with untreated metastatic prostate carcinoma. The tumours were histologically graded by an independent pathologist. Expression of mRNA for E-cadherin and beta-catenin was detected within the tumour cells using in-situ hybridization with a 35S-labelled cDNA probe. The expression of E-cadherin and beta-catenin were graded as uniform, heterogeneous or negative. RESULTS: The mRNA for E-cadherin was expressed in 13 of 14 primary carcinomas and 11 bone metastases; beta-catenin was expressed by 13 and nine, respectively. Of the primary tumours, nine expressed E-cadherin and beta-catenin uniformly; in contrast, all metastases had down-regulated E-cadherin and/or beta-catenin. CONCLUSIONS: The down-regulation of E-cadherin and beta-catenin are a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. However, this does not appear to be reflected in the expression of these molecules in the primary tumours.


This item appears in the following Collection(s)

Show simple item record